HCRI medical researchers led by Dr. Iris Lavon – Head of the Molecular Neuro-Oncology lab at Sharett Oncology Institute and Dr. Aviad Zick – Senior Medical Oncologist at Sharett Oncology Institute, have completed a significant study on sarcoma classification that has the potential to revolutionize the diagnosis and treatment of other cancer types.
Methodology: Utilizing Oxford Nanopore technology, the HCRI team achieved a classification rate of 78%. This was based on methylation and copy-number variation data from low-coverage whole-genome sequencing.
The Challenge: Sarcoma classification has historically been challenging, sometimes leading to treatment delays.
Advantages of Oxford Nanopore: The technology stands out due to its compactness, speed, and ability to identify diverse genomic patterns. Its relative affordability makes it a viable option for many laboratories.
This research is another important leadership milestone for HCRI and its mission to advance cancer diagnosis and care. Thanks to all who helped to make this advancement possible.
Read the full article >> here
Head of the Molecular Neuro-Oncology lab at Sharett Oncology Institute
Senior Medical Oncologist at Sharett Oncology Institute
